Table 5

Modulation of RAR-β expression by biopsy site and participant

Analysis unitTreatmentRAR-β expression (baseline/6 months)TimeRAR-β loss (%)
−/−−/++/−+/+
Biopsy site4-HPRa24483588Baseline72/195 (36.9)
6 months59/195 (30.3)
Placeboa16513885Baseline67/190 (35.3)
6 months54/190 (28.4)
Participantb4-HPRc17566Baseline22/34 (64.7)
6 months23/34 (67.6)
Placeboc161172Baseline27/36 (75.0)
6 months23/36 (63.9)
  • a ,

  • c The modulation of RAR-β expression was not significantly different between treatment groups by biopsy site (

  • a P = 0.96) or by participant (

  • c P = 0.35) using the GEE method.

  • b When using participant as the analysis unit, we considered undetectable RAR-β expression at any of the six biopsy sites as a criterion for RAR-β loss in participant.